October 7, 2021
Natick biotech receives $30M in funding from Hong Kong firm
Photo | Courtesy of Moderna
A biopharma worker
By Katherine Hamilton
Natick cancer treatment company Affylmmune Therapeutics, Inc. announced Thursday it has closed a $30-million Series A+ funding by ORI Capital Limited to advance a cancer treatment study.
The funding will advance the Phase 1 study of AIC1000, a treatment for anaplastic thyroid cancer.
AffyImmune plans to double its headcount over the next nine months with a focus on expanding its leadership teams, said the announcement.
As part of the investment, ORI Capital’s director, Elaine Yang, will join AffyImmune’s board of directors.
ORI Capital is a healthcare fund manager based in Hong Kong.
WBJ Web Partners
Most Recent
Most Recent
0 Comments